About TScan Therapeutics
TScan Therapeutics is a company based in Boston (United States) founded in 1995. It operates as a HealthTech. TScan Therapeutics has raised $158.3 million across 3 funding rounds from investors including Novartis, Bessemer Venture Partners and BlackRock. The company has 194 employees as of December 31, 2024. TScan Therapeutics offers products and services including TCR-T Therapy for Hematologic Malignancies and TCR-T Therapy for Solid Tumors. TScan Therapeutics operates in a competitive market with competitors including Poseida Therapeutics, Juno Therapeutics, Lyell Immunopharma, Hummingbird Bioscience and Autolus, among others.
- Headquarter Boston, United States
- Employees 194 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Tscan Therapeutics, Inc.
-
Annual Revenue
$2.82 M-86.62as on Dec 31, 2024
-
Net Profit
$-127.5 M-42.91as on Dec 31, 2024
-
EBITDA
$-130.71 M-48.37as on Dec 31, 2024
-
Total Equity Funding
$158.3 M (USD)
in 3 rounds
-
Latest Funding Round
$100 M (USD), Series C
Jan 25, 2021
-
Investors
Novartis
& 9 more
-
Employee Count
194
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of TScan Therapeutics
TScan Therapeutics is a publicly listed company on the NASDAQ with ticker symbol TCRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of TScan Therapeutics
TScan Therapeutics offers a comprehensive portfolio of products and services, including TCR-T Therapy for Hematologic Malignancies and TCR-T Therapy for Solid Tumors. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
TCR-T therapies are developed for hematologic cancer treatment.
TCR-T therapies are designed for solid tumor treatment.
Unlock access to complete
Unlock access to complete
Funding Insights of TScan Therapeutics
TScan Therapeutics has successfully raised a total of $158.3M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $100 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $100.0M
-
First Round
First Round
(24 Jul 2019)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2021 | Amount | Series C - TScan Therapeutics | Valuation | BlackRock , RA Capital Management | |
| Jan, 2020 | Amount | Series B - TScan Therapeutics | Valuation | Pitango , Astellas Venture Management | |
| Jul, 2019 | Amount | Series B - TScan Therapeutics | Valuation | Novartis |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in TScan Therapeutics
TScan Therapeutics has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Novartis, Bessemer Venture Partners and BlackRock. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is directed toward healthcare companies by Longwood Fund.
|
Founded Year | Domain | Location | |
|
Life-Sciences focused early and growth stage VC firm funding companies in China & the US
|
Founded Year | Domain | Location | |
|
Venture capital investments and support for entrepreneurs in technology and innovation sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by TScan Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - TScan Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Tscan Therapeutics Comparisons
Competitors of TScan Therapeutics
TScan Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Poseida Therapeutics, Juno Therapeutics, Lyell Immunopharma, Hummingbird Bioscience and Autolus, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Antibody drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Tscan Therapeutics
Frequently Asked Questions about TScan Therapeutics
When was TScan Therapeutics founded?
TScan Therapeutics was founded in 1995 and raised its 1st funding round 24 years after it was founded.
Where is TScan Therapeutics located?
TScan Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Is TScan Therapeutics a funded company?
TScan Therapeutics is a funded company, having raised a total of $158.3M across 3 funding rounds to date. The company's 1st funding round was a Series B of $23.3M, raised on Jul 24, 2019.
How many employees does TScan Therapeutics have?
As of Dec 31, 2024, the latest employee count at TScan Therapeutics is 194.
What is the annual revenue of TScan Therapeutics?
Annual revenue of TScan Therapeutics is $2.82M as on Dec 31, 2024.
What does TScan Therapeutics do?
TScan Therapeutics is engaged in creating life-changing T-cell therapies for patients by leveraging the human immune system. The company is dedicated to advancing a pipeline of TCR-T therapy candidates for hematologic malignancies and solid tumors. Their proprietary platform is utilized to discover anti-cancer T cell receptors from patients with exceptional immunotherapy responses. Solutions are developed to address critical needs in cancer treatment through innovative biotechnological approaches.
Who are the top competitors of TScan Therapeutics?
TScan Therapeutics's top competitors include Hummingbird Bioscience, Juno Therapeutics and Lyell Immunopharma.
What products or services does TScan Therapeutics offer?
TScan Therapeutics offers TCR-T Therapy for Hematologic Malignancies and TCR-T Therapy for Solid Tumors.
Is TScan Therapeutics publicly traded?
Yes, TScan Therapeutics is publicly traded on NASDAQ under the ticker symbol TCRX.
Who are TScan Therapeutics's investors?
TScan Therapeutics has 10 investors. Key investors include Novartis, Bessemer Venture Partners, BlackRock, RA Capital, and Longwood Fund.
What is TScan Therapeutics's ticker symbol?
The ticker symbol of TScan Therapeutics is TCRX on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.